Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Umoja Biopharma to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference | ||
| By: GlobeNewswire - 19 Mar 2024 | Back to overview list |
|
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced that the Company will present a corporate overview at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024. Presentation Details: Date/Time: Tuesday, March 26, 2024, at 4:30 p.m. ET Members of Umoja’s leadership team will also be available for one-on-one meetings. If you are interested in a meeting, please reach out via the H.C. Wainwright Conference Platform. About Umoja Biopharma Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/. Investors Grace Kim, Ph.D. Laurence Watts Media Jason Braco, Ph.D. 
|
||
|
||
 | Back to overview list | |